LB Pharmaceuticals Inc
Last updated September 27, 2026
Organization details
- Legal name
- LB Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LBRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001691082
Board of directors
-
Heather D. Turner · Director · Chief Executive OfficerSince 2025
-
J. Scott Garland · DirectorSince 2025
-
Ran Nussbaum · DirectorSince 2025
-
Rebecca Luse · DirectorSince 2025
-
Rekha Hemrajani · DirectorSince 2025
-
Robert A. Lenz · DirectorSince 2026
-
Robert R. Ruffolo · DirectorSince 2025
-
William P. Kane Jr. · DirectorSince 2025
-
Zachary Prensky · DirectorSince 2025
Chief executives
Heather D. Turner
· Chief Executive Officer
Since September 2025
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.3%
-
93.4%
Board connections
6 of this board's directors also sit on 10 other boards.
- via J. Scott Garland and Rekha Hemrajani
- via Heather D. Turner
- via Rekha Hemrajani
- via Robert R. Ruffolo
- via J. Scott Garland
- via Ran Nussbaum
- via Rekha Hemrajani
- via Robert A. Lenz
- via J. Scott Garland
- via Ran Nussbaum
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 12, 2025 | Deep Track Capital, LP 10% owner | Derivative conversion | +686,138 | — | — |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Derivative conversion | +411,681 | — | — |
| Sep 12, 2025 | Ran Nussbaum Director | Derivative conversion | +411,681 | — | — |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Derivative conversion | +547,648 | — | — |
| Sep 12, 2025 | Deep Track Capital, LP 10% owner | Open-market purchase | +2,000,000 | $15.00 | $30,000,000 |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Sep 12, 2025 | Ran Nussbaum Director | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Derivative conversion | +1,262 | — | — |
| Sep 12, 2025 | Deep Track Capital, LP 10% owner | Open-market purchase | +666,666 | $15.00 | $9,999,990 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Open-market purchase | +332,566 | $15.00 | $4,988,490 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. 10% owner | Open-market purchase | +767 | $15.00 | $11,505 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.